Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reubi, J. C.
Right arrow Articles by Gugger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reubi, J. C.
Right arrow Articles by Gugger, M.
Clinical Cancer Research Vol. 8, 1139-1146, April 2002
© 2002 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Bombesin Receptor Subtypes in Human Cancers

Detection with the Universal Radioligand 125I-[D-TYR6, ß-ALA11, PHE13, NLE14] Bombesin(6–14)

Jean Claude Reubi1, Sandra Wenger, Jacqueline Schmuckli-Maurer, Jean-Claude Schaer and Mathias Gugger

Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, CH-3010 Berne, Switzerland

Purpose: Bombesin and bombesin receptors have been shown to play a role in cancer. Whereas the gastrin-releasing peptide (GRP) receptor is a bombesin receptor subtype frequently expressed by tumors, the other three subtypes, the neuromedin B (NMB), BB3, and BB4 receptors, have been poorly investigated in human tissues.

Experimental Design: We investigated 161 human tumors for their bombesin receptor subtype expression using in vitro receptor autoradiography with the universal bombesin radioligand 125I-[D-Tyr6, ß-Ala11, Phe13, Nle14]bombesin(6–14) in displacement experiments with unlabeled GRP, bombesin, NMB, and [D-Tyr6, ß-Ala11, Phe13, Nle14]bombesin(6–14). The distinct rank order of potencies of these analogues for each receptor subtype allows us to identify the predominant subtype expressed by each tumor.

Results: Twelve of 12 prostate cancers, 41 of 57 breast cancers, and 5 of 5 gastrinomas expressed predominantly GRP receptors; 11 of 24 intestinal, 1 of 26 bronchial, and 1 of 1 thymic carcinoids had preferentially NMB receptors; 9 of 26 bronchial carcinoids, 1 large cell neuroendocrine lung carcinoma, and 4 of 9 small cell lung carcinomas had preferentially BB3 receptors, whereas 3 of 9 small cell lung carcinomas had GRP receptors. Renal cell carcinomas had GRP receptors in 6 of 16 cases and BB3 receptors in 4 of 16 cases. Finally, 2 of 10 Ewing sarcomas had BB3 receptors. In situ hybridization detected BB3 receptor mRNA in neuroendocrine tumors expressing the BB3 protein.

Conclusions: This is the first study detecting the proteins of BB3, NMB, and GRP receptors in a group of human tumors using differential binding techniques. Particularly relevant is the BB3 expression in lung carcinoids and other neuroendocrine lung tumors, whereas gastrointestinal carcinoids preferably express NMB receptors. These tumors may be targets for diagnostic and radiotherapeutic applications of subtype-selective bombesin analogues.




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya
International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States
Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. Cescato, T. Maina, B. Nock, A. Nikolopoulou, D. Charalambidis, V. Piccand, and J. C. Reubi
Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting
J. Nucl. Med., February 1, 2008; 49(2): 318 - 326.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Cornelio, R Roesler, and G Schwartsmann
Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy
Ann. Onc., September 1, 2007; 18(9): 1457 - 1466.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. de Visser, W. M. van Weerden, C. M.A. de Ridder, S. Reneman, M. Melis, E. P. Krenning, and M. de Jong
Androgen-Dependent Expression of the Gastrin-Releasing Peptide Receptor in Human Prostate Tumor Xenografts
J. Nucl. Med., January 1, 2007; 48(1): 88 - 93.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. A. Mantey, N. Gonzalez, M. Schumann, T. K. Pradhan, L. Shen, D. H. Coy, and R. T. Jensen
Identification of Bombesin Receptor Subtype-Specific Ligands: Effect of N-Methyl Scanning, Truncation, Substitution, and Evaluation of Putative Reported Selective Ligands
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 980 - 989.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. J. Desai, A.-H. Ma, C. G. Tepper, H.-W. Chen, and H.-J. Kung
Inappropriate Activation of the Androgen Receptor by Nonsteroids: Involvement of the Src Kinase Pathway and Its Therapeutic Implications
Cancer Res., November 1, 2006; 66(21): 10449 - 10459.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. W. Moody, L.-C. Sun, S. A. Mantey, T. Pradhan, L. V. Mackey, N. Gonzales, J. A. Fuselier, D. H. Coy, and R. T. Jensen
In Vitro and in Vivo Antitumor Effects of Cytotoxic Camptothecin-Bombesin Conjugates Are Mediated by Specific Interaction with Cellular Bombesin Receptors
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1265 - 1272.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. E. Lantry, E. Cappelletti, M. E. Maddalena, J. S. Fox, W. Feng, J. Chen, R. Thomas, S. M. Eaton, N. J. Bogdan, T. Arunachalam, et al.
177Lu-AMBA: Synthesis and Characterization of a Selective 177Lu-Labeled GRP-R Agonist for Systemic Radiotherapy of Prostate Cancer
J. Nucl. Med., July 1, 2006; 47(7): 1144 - 1152.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Fleischmann, B. Waser, J.-O. Gebbers, and J. C. Reubi
Gastrin-Releasing Peptide Receptors in Normal and Neoplastic Human Uterus: Involvement of Multiple Tissue Compartments
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4722 - 4729.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Maina, B. A. Nock, H. Zhang, A. Nikolopoulou, B. Waser, J.-C. Reubi, and H. R. Maecke
Species Differences of Bombesin Analog Interactions with GRP-R Define the Choice of Animal Models in the Development of GRP-R-Targeting Drugs
J. Nucl. Med., May 1, 2005; 46(5): 823 - 830.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Schuhmacher, H. Zhang, J. Doll, H. R. Macke, R. Matys, H. Hauser, M. Henze, U. Haberkorn, and M. Eisenhut
GRP Receptor-Targeted PET of a Rat Pancreas Carcinoma Xenograft in Nude Mice with a 68Ga-Labeled Bombesin(6-14) Analog
J. Nucl. Med., April 1, 2005; 46(4): 691 - 699.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
W P ter Beek, E S M Muller, R A van Hogezand, I Biemond, and C B H W Lamers
Gastrin releasing peptide receptor expression is decreased in patients with Crohn's disease but not in ulcerative colitis
J. Clin. Pathol., October 1, 2004; 57(10): 1047 - 1051.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Zhang, J. Chen, C. Waldherr, K. Hinni, B. Waser, J. C. Reubi, and H. R. Maecke
Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors
Cancer Res., September 15, 2004; 64(18): 6707 - 6715.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. A. Mantey, D. H. Coy, L. K. Entsuah, and R. T. Jensen
Development of Bombesin Analogs with Conformationally Restricted Amino Acid Substitutions with Enhanced Selectivity for the Orphan Receptor Human Bombesin Receptor Subtype 3
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1161 - 1170.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. W. Moody, S. A. Mantey, T. K. Pradhan, M. Schumann, T. Nakagawa, A. Martinez, J. Fuselier, D. H. Coy, and R. T. Jensen
Development of High Affinity Camptothecin-Bombesin Conjugates That Have Targeted Cytotoxicity for Bombesin Receptor-containing Tumor Cells
J. Biol. Chem., May 28, 2004; 279(22): 23580 - 23589.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
E. P. KRENNING, D. J. KWEKKEBOOM, R. VALKEMA, S. PAUWELS, L. K. KVOLS, and M. DE JONG
Peptide Receptor Radionuclide Therapy
Ann. N.Y. Acad. Sci., April 1, 2004; 1014(1): 234 - 245.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. C. Reubi
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Endocr. Rev., August 1, 2003; 24(4): 389 - 427.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. J. Hoffman, H. Gali, C. J. Smith, G. L. Sieckman, D. L. Hayes, N. K. Owen, and W. A. Volkert
Novel Series of 111In-Labeled Bombesin Analogs as Potential Radiopharmaceuticals for Specific Targeting of Gastrin-Releasing Peptide Receptors Expressed on Human Prostate Cancer Cells
J. Nucl. Med., May 1, 2003; 44(5): 823 - 831.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.